Literature DB >> 2995044

How much does liver disease affect the pharmacokinetics of adriamycin?

S B Kaye, J Cummings, D J Kerr.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2995044     DOI： 10.1016/0277-5379(85)90103-8

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN： 0277-5379


× No keyword cloud information.
  4 in total

1.  Bayesian estimation of doxorubicin pharmacokinetic parameters.

Authors:  F Bressolle; P Ray; J M Jacquet; J Brès; M Galtier; D Donadio; J Jourdan; J F Rossi
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  A limited sampling procedure for estimating adriamycin pharmacokinetics in cancer patients.

Authors:  M C Launay; G Milano; A Iliadis; M Frenay; N Namer
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640

3.  Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters.

Authors:  P J Johnson; N Dobbs; C Kalayci; M C Aldous; P Harper; E M Metivier; R Williams
Journal:  Br J Cancer       Date:  1992-05       Impact factor: 7.640

4.  An evaluation of hepatic extraction and clearance of doxorubicin.

Authors:  D A August; N Verma; M A Vaertan; R Shah; D E Brenner
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.